Literature DB >> 1486675

Comparison of combinations of parenteral artemisinin derivatives plus oral mefloquine with intravenous quinine plus oral tetracycline for treating cerebral malaria.

K Win1, M Than, Y Thwe.   

Abstract

A total of 141 cases of strictly defined cerebral malaria were studied in a controlled trial of three regimens: (1) intramuscular artemether plus oral mefloquine, (2) intravenous artesunate plus oral mefloquine, and (3) intravenous quinine (with or without an initial loading dose) plus oral tetracycline. The overall mortalities in each group were 14%, 8.3% and 34.3% respectively. The average parasite clearance time was 27.30 +/- 19.62 hours in regimen 1, 41.84 +/- 17.55 hours in regimen 2, and 47.30 +/- 21.95 hours in regimen 3. No recrudescence was observed in regimens 1 and 2, but 12.1% recrudesced in the third.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486675      PMCID: PMC2393408     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  3 in total

1.  The effect of mefloquine-artemether compared with quinine on patients with complicated falciparum malaria.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  1988       Impact factor: 2.184

2.  A controlled clinical trial of artemether (qinghaosu derivative) versus quinine in complicated and severe falciparum malaria.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

3.  The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice.

Authors:  A N Chawira; D C Warhurst; B L Robinson; W Peters
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

  3 in total
  15 in total

Review 1.  Recent advances in tropical medicine.

Authors:  D N Lockwood; G Pasvol
Journal:  BMJ       Date:  1994-06-11

Review 2.  Artemisinin derivatives for treating severe malaria.

Authors:  H M McIntosh; P Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy.

Authors:  S R Meshnick; T E Taylor; S Kamchonwongpaisan
Journal:  Microbiol Rev       Date:  1996-06

Review 4.  Artesunate versus quinine for treating severe malaria.

Authors:  David Sinclair; Sarah Donegan; Rachel Isba; David G Lalloo
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

Review 5.  Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria.

Authors:  P J de Vries; T K Dien
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

6.  Comparative efficacy and safety of the artemisinin derivatives compared to quinine for treating severe malaria in children and adults: A systematic update of literature and network meta-analysis.

Authors:  Nicholas Nyaaba; Nana Efua Andoh; Gordon Amoh; Dominic Selorm Yao Amuzu; Mary Ansong; José M Ordóñez-Mena; Jennifer Hirst
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

7.  Clinical experience with intravenous quinine, intramuscular artemether and intravenous artesunate for the treatment of severe malaria in Thailand.

Authors:  Srivicha Krudsood; Polrat Wilairatana; Suparp Vannaphan; Sombat Treeprasertsuk; Udomsak Silachamroon; Weerapong Phomrattanaprapin; Victor R Gourdeuk; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-03       Impact factor: 0.267

Review 8.  Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria.

Authors:  L B Barradell; A Fitton
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 9.  Progress in the research of artemisinin-related antimalarials: an update.

Authors:  H J Woerdenbag; N Pras; W van Uden; T E Wallaart; A C Beekman; C B Lugt
Journal:  Pharm World Sci       Date:  1994-08-05

10.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.

Authors:  Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White
Journal:  Lancet       Date:  2010-11-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.